Home  >  TVI-BRAIN-1

TVI-BRAIN-1 Overview

TVAX®’s lead candidate (TVI-Brain-1) is being evaluated for the treatment of brain cancer and targets glioblastomas

The drug candidate, which has received orphan product designation for the treatment of central nervous system cancer, is supported by positive Phase 2 clinical data, as well as extensive preclinical and Phase 1 safety studies.  Based on these supportive data, the company has been authorized by the United States Food and Drug Administration (FDA) to conduct pivotal Phase 3 trials for TVI-Brain-1 to support the therapy’s potential FDA approval.